NCT02428608View on ClinicalTrials.gov

Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006

PHASE2CompletedINTERVENTIONAL
Enrollment

570

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2016

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

DWP-450 (Botulinum purified neurotoxin, Type A)

Botulinum toxin, Type A

Trial Locations (1)

68144

The Advanced Skin Research Center at Skin Specialists, PC, Omaha

Sponsors

Lead Sponsor

Evolus, Inc.

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Evolus, Inc.

INDUSTRY